Lyvgen Biopharma Holdings Limited

Quick facts

Phase 2 pipeline

• LVGN6051 Monoclonal Antibody Injection · Oncology
  LVGN6051 targets the PD-1 receptor to inhibit cancer cell growth and immune evasion.

Phase 1 pipeline

• LVGN6051
• LVGN7409

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Lyvgen Biopharma Holdings Limited portfolio CI brief
• Lyvgen Biopharma Holdings Limited pipeline updates RSS

Related

• Sector hub: All tracked pharma companies